Lactococcus rhamnosus, particularly L. rhamnosus GG (ATCC 53103), has been investigated for its potential role in supporting or treating gastric and peptic ulcers, especially those associated with Helicobacter pylori infection. Several clinical studies and meta-analyses indicate that supplementation with L. rhamnosus as an adjunct to standard triple therapy for H. pylori-related ulcers can improve eradication rates and reduce therapy-associated side effects, such as diarrhea and nausea. The proposed mechanisms include competitive inhibition of pathogen adhesion, modulation of the host immune response, and enhancement of mucosal barrier function.

However, while these probiotics show promise in improving patient comfort and potentially supporting ulcer healing indirectly, the primary evidence supports their adjunctive use rather than as standalone therapy for ulcers. The direct ulcer-healing effects of L. rhamnosus are less well established, with most benefits arising from their impact on the underlying infectious and inflammatory components. There is moderate quality evidence (rated here as 3/5) supporting their use as a supportive measure, particularly in the context of H. pylori-associated ulcers, but not as a primary or sole treatment for gastric or duodenal ulcers.

References:

• Szajewska H, et al. World J Gastroenterol. 2016;22(5):1971–1981.
• Lesbros-Pantoflickova D, et al. Aliment Pharmacol Ther. 2007;25(2):155–168.
• Ojetti V, et al. J Clin Gastroenterol. 2012;46 Suppl:S34–39.